Wilmington Savings Fund Society FSB Has $9.35 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Wilmington Savings Fund Society FSB grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 103.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 323,016 shares of the biopharmaceutical company’s stock after acquiring an additional 164,032 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Pfizer were worth $9,348,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in PFE. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Gladius Capital Management LP grew its holdings in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP bought a new position in Pfizer during the 2nd quarter worth $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the second quarter worth $34,000. Finally, Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer in the third quarter valued at about $35,000. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Stock Performance

Pfizer stock opened at $25.31 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $143.43 billion, a PE ratio of 34.12, a P/E/G ratio of 0.71 and a beta of 0.65. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s 50-day moving average price is $27.29 and its two-hundred day moving average price is $28.31.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company posted ($0.17) EPS. As a group, analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 8th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.64%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Analysts Set New Price Targets

A number of equities analysts recently commented on PFE shares. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.43.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.